ClinicalTrials.gg
CompletedNCT05381948DAVIO2Updated Oct 15, 2025Results posted

Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD)

A Phase 2 interventional study of EYP-1901 and Aflibercept 2mg/0.05mL Inj,Oph in Wet Age-related Macular Degeneration, sponsored by EyePoint Pharmaceuticals, Inc.. Completed at 67 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-10-15.

Sponsored by EyePoint Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
127th of 491
161 · median 55
Started
2022
with 35 others
Phase 2
138 of 645
14 open now
Registered
512th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 127th largest by enrollment of the 491 interventional ones that give a count, is one of 36 that started in 2022, is one of 138 in phase 2, and was the 512th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

This is a phase 2 randomized, double -masked study comparing the efficacy of EYP-1901 at 2 dose levels: 2060 microgram (mcg) and 3090 mcg against aflibercept.

Read the detailed description

This study is evaluating the 2 doses of EYP-1901 against aflibercept in a randomized study.

03

Conditions studied

  • Wet Age-related Macular Degeneration

Keywords

  • wAMD
  • EYP-1901
  • EyePoint
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented diagnosis of wAMD in the study eye, with disease onset any time prior to the Screening Visit.
  • Documented anatomical response (that is, reduction in fluid on [spectral-domain - optical coherence tomography (SD-OCT)] to previous intravitreal anti-vascular endothelial growth factor (anti-VEGF) injections in the study eye prior to the Screening Visit.
  • Previously treated with at least 2 anti-VEGF intravitreal injections (that is, bevacizumab, ranibizumab, aflibercept or faricimab) for wAMD per standard of care in the study eye within 6 months prior to the Screening Visit.
  • Received previous anti-VEGF therapy 2 to 5 weeks (14 to 35 days) in the study eye prior to Screening Visit, but no more than 42 days prior to randomization to study treatment on Day 1.
  • Best corrected visual acuity (BCVA) early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 35 letters (20/200 Snellen equivalent) to 85 letters (20/20 Snellen equivalent) in the study eye at the Screening Visit and on Day 1.
  • Able to understand, and willingness to sign, the and to provide access to personal health information via Health Insurance Portability and Accountability Act (HIPAA) authorization.
  • Willingness and ability to comply with all scheduled visits, restrictions, and assessments.
  • For women of , or men with female partners of childbearing potential, agreement to the use of an appropriate form of at the Screening Visit and for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • History of pars plana vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in the study eye.
  • Prior treatment with Visudyne® (verteporfin), external beam radiation therapy, or transpupillary thermotherapy in the study eye.
  • Previous treatment with intravitreal injection or device implantation in the study eye.
  • Previous focal laser photocoagulation used for AMD treatment in the study eye.
  • Total choroidal neovascularization (CNV) lesion size >12 disc areas [30.5 millimeter square (mm\^2)] as assessed by fluorescein angiography (FA) in the study eye at the Screening Visit.
  • Central subfield thickness (CST) >350 micrometer (mcm) in the study eye at the Screening Visit or Day 1.
  • Intraretinal cystic fluid >25 mcm in diameter involving the central subfield and/or disruption of normal morphology (loss of foveal depression, disruption of external limiting membrane) secondary to cystic intraretinal fluid within the central subfield, in the study eye at the Screening Visit. Diffuse (non-cystic) intraretinal fluid would not be excluded.
  • Subretinal hemorrhage in the subfoveal/juxtafoveal location and hemorrhage greater than 1 disc are (1.8 mm\^2) if located less than 200 mcm from the foveal center in the study eye at either the Screening Visit or Day 1.
  • Subfoveal fibrosis, atrophy, or scarring in the center subfield in the study eye at the Screening Visit.
  • Fibrosis >50% of the total lesion, in the study eye at the Screening Visit.
  • Retinal pigment epithelium detachment (RPED) thickness >400 mcm at any point within 3 mm of the foveal center in the study eye at either the Screening Visit or Day 1.
  • Retinal pigment epithelial tear in the study eye at the Screening Visit or Day 1.
  • Any concurrent intraocular condition in the study eye (e.g., cataract or glaucoma) that, in the opinion of the investigator, would have either required surgical intervention during the study to prevent or treat visual loss that might result from that condition or affected interpretation of the study results.
  • Historical or active intraocular inflammation (grade trace or above) in the study eye, other than expected findings from routine cataract surgery.
  • History of vitreous hemorrhage in the study eye within 12 weeks prior to the Screening Visit.
  • History of rhegmatogenous retinal detachment or treatment for retinal detachment or macular hole (stage 3 or 4) in the study eye.
  • Aphakia or pseudophakia with the absence of the posterior capsule in the study eye (YAG capsulotomy is permitted).
  • Spherical equivalent of the refractive error in the study eye demonstrating >8 diopters of myopia.
  • For subjects who have undergone prior refractive or cataract surgery in the study eye, preoperative refractive error in the study eye exceeding 8 diopters of myopia.
  • Intraocular surgery (including cataract surgery) in the study eye within 12 weeks prior to the Screening Visit.
  • Uncontrolled ocular hypertension or glaucoma in the study eye (defined as intraocular pressure (IOP) >25 mm of mercury (mmHg) or a cup to disc ratio >=0.8, despite treatment with 2 or more classes of antiglaucoma medication) and any such condition which the Investigator feels may require a glaucoma-filtering surgery while in the study.
  • History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery in the study eye.
  • History of corneal transplant in the study eye.
  • BCVA using ETDRS charts \<30 letters (20/250 Snellen equivalent) in the fellow eye.
  • Worsening of BCVA ≥10 ETDRS letters in the study eye from the Screening Visit to Day 1.
  • Presence of CNV in either eye due to other causes aside from wAMD at the Screening Visit.
  • Treatment with Visudyne® in the fellow eye \<7 days prior to the Screening Visit.
  • Prior participation in a clinical trial involving anti-angiogenic drugs administered in either eye or systemically within 8 weeks prior to the Screening Visit.
  • Prior participation in a clinical trial involving investigational ocular gene therapy trial for either eye.
  • History of idiopathic or -associated uveitis in either eye.
  • Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.
  • Presence of any other systemic or ocular condition which, in the judgment of the investigator, could make the subject inappropriate for entry into this study.
  • Uncontrolled blood pressure (defined as systolic >180 mmHg and/or diastolic >100 mmHg), based on the average of three readings taken with the subject in a resting state.
  • Myocardial infarction within 6 months prior to screening or New York Hospital Association () Class III or IV heart failure, uncontrolled atrial fibrillation, uncontrolled angina, cardiomyopathy, ventricular arrhythmias or other cardiac conditions which, in the judgment of the investigator, could make the subject inappropriate for entry into this study.
  • Serious non-healing wound, ulcer, or bone fracture.
  • (HbA1c) greater than 7% at the Screening Visit.
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of EYP-1901.
  • Current treatment for any active systemic infection.
  • Previous use of any systemic anti-VEGF agents or intraocular brolucizumab in the study eye.
  • Use of oral corticosteroids (prednisone >10 mg/day or equivalent) within 30 days prior to the Screening Visit.
  • History or presence of bleeding disorders, including disorders, hemorrhage, acquired or hereditary coagulation disorders (including deep vein thrombosis and pulmonary embolisms), acquired or hereditary vascular disorders, stroke, or .
  • Excluding certain skin cancers (specifically, basal cell carcinoma and squamous cell carcinoma), any receiving treatment, or in remission less than 5 years prior to study entry.
  • History of allergy to fluorescein, not amenable to treatment.
  • Inability to obtain fundus photographs, FA, fundus autofluorescence, or SD-OCT images of sufficient quality to be analyzed and graded by the Central Reading Center.
  • Historical or active diagnosis of any medical or psychological condition that could interfere with the ability of the subject to give , or to comply with study or follow-up procedures.
  • Previous participation in any ocular or non-ocular (systemic) disease studies of investigational drugs within 30 days prior to the Screening Visit (excluding vitamins and minerals).
  • Use of anti-mitotic or anti-metabolite therapy within 30 days or 5 elimination half-lives of the Screening Visit, whichever is longer.
  • Intolerance, , or to topical anesthetics, dyes, povidone iodine, mydriatic medications, or any of the ingredients of the EYP-1901 insert.
  • Requirement for continuous use of any protocol-prohibited medications or treatments.
  • Pregnant or nursing females; females of who are unwilling or unable to use an acceptable method of during the study as outlined in this protocol.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    EYP-1901 2060 mcg

    EYP-1901 2060 mcg, single dose

    Drug: EYP-1901

  • Experimental
    EYP-1901 3090 mcg

    EYP-1901 3090 mcg, single dose

    Drug: EYP-1901

  • Active comparator
    Aflibercept

    Aflibercept 2 milligram (mg) \[0.05 milliliter (mL)\] every 8 weeks

    Drug: Aflibercept 2mg/0.05mL Inj,Oph

Interventions

  • Intravitreal Injection

  • DrugAflibercept 2mg/0.05mL Inj,Oph

    Drug page: Aflibercept

    Intravitreal Injection

    Also known as: Eylea

06

What researchers measure

Primary outcomes

  1. Average Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 32

    The BCVA was measured according to the standard procedure originally developed for Early Treatment Diabetic Retinopathy Study (ETDRS). The ETDRS letter score calculated when 20 or more letters were read correctly at 4.0 meters; the visual acuity letter score was equal to the total number of letters read correctly at 4.0 meters plus 30. The score ranges from 0 (worse) to 100 (best). Higher scores indicate positive outcome measure. Baseline was defined as the last non-missing measurement before the initiation of study treatment.

    Time frame: Baseline (Day 1) and Weeks 28 and 32

Secondary outcomes

  1. Change From Baseline in Best Corrected Visual Acuity up to Week 56

    The BCVA was measured according to the standard procedure originally developed for ETDRS. The ETDRS letter score calculated when 20 or more letters were read correctly at 4.0 meters; the visual acuity letter score was equal to the total number of letters read correctly at 4.0 meters plus 30. The score ranges from 0 (worse) to 100 (best). Higher scores indicate positive outcome measure. Baseline was defined as the last non-missing measurement before the initiation of study treatment.

    Time frame: Baseline (Day 1) and Weeks 32 and 56

  2. Percentage of Subjects With >=5, >=10, and >=15 BCVA Letter Change From Baseline up to Week 56

    The BCVA was measured according to the standard procedure originally developed for ETDRS. The ETDRS letter score calculated when 20 or more letters were read correctly at 4.0 meters; the visual acuity letter score was equal to the total number of letters read correctly at 4.0 meters plus 30. The score ranges from 0 (worse) to 100 (best). Higher scores indicate positive outcome measure. Baseline was defined as the last non-missing measurement before the initiation of study treatment.

    Time frame: Baseline (Day 1) and Weeks 32 and 56

  3. Percentage of Subjects Not Receiving Supplemental Injection of Aflibercept up to Week 56

    Supplemental therapy was any unscheduled injection of aflibercept, whether or not a subject had met rescue criteria. For the aflibercept arm, any aflibercept injection following Week 8 which did not occur at Weeks 16, 24, 32, 40, 48, or 56, was supplemental therapy. For either of the EYP-1901 arms, any aflibercept injection following the Week 8 visit was supplemental therapy.

    Time frame: Weeks 32 and 56

  4. Median Time to First Supplemental Aflibercept Injection in the Study Eye Following the EYP-1901 Dose at Week 8

    Time to first supplemental aflibercept injection following Week 8 study treatment was defined as the date of the first supplemental aflibercept injection minus the date of the Week 8 study treatment administration, divided by 7 days per week. Subjects who did not receive any supplemental aflibercept injection following study treatment administration at Week 8 were censored at their date of last visit (those who completed) or date of last contact (those who discontinued the study early).

    Time frame: From Week 8 to Week 56

  5. Number of Aflibercept Intravitreal Injections up to Week 56 (Including Loading Dose)

    Normalized number of aflibercept injections including loading dose was calculated as (number of aflibercept injections received plus all loading doses received) / (time within study period in months), multiplied by 6 months (Week 32) or 12 months (Week 56).

    Time frame: Weeks 32 and 56

  6. Mean Change From Baseline in Central Subfield Thickness (CST) by Spectral-Domain - Optical Coherence Tomography (SD-OCT) up to Week 56

    The SD-OCT assessments in study eye was taken by a study-certified OCT technician according to the standardized procedures described in the Study Manual. Baseline was defined as the last non-missing measurement before the initiation of study treatment.

    Time frame: Baseline (Day 1) and Weeks 32 and 56

  7. Change From Baseline in Height of Subretinal Fluid by Spectral-Domain - Optical Coherence Tomography up to Week 56

    The SD-OCT assessments in study eye was taken by a study-certified OCT technician according to the standardized procedures described in the Study Manual. Baseline was defined as the last non-missing measurement before the initiation of study treatment.

    Time frame: Baseline (Day 1) and Weeks 32 and 56

  8. Percentage of Subjects With No Detectable Intraretinal Fluid/Cysts in the Central Subfield up to Week 56

    The percentage of subjects with no detectable intraretinal fluid/cysts in the central subfield were summarized by scheduled visit and for any time post-baseline visits. Intraretinal fluid was assessed for the categories 'Absent', 'Present, not clinically significant', 'Present, clinically significant' and 'Not Done'. If intraretinal fluid assessment at any scheduled visit fell under the category 'Absent or Present, not clinically significant', then it was considered as no detectable intraretinal fluid in that scheduled visit.

    Time frame: Weeks 32 and 56

  9. Change From Baseline in Total Lesion Area by Fluorescein Angiography (FA) up to Week 56

    The total lesion area was defined as the active vascular component \[classic and occult choroidal neovascularization (CNV)\] and the non-vascular/fibrotic component (fibrosis, serous pigment epithelial detachment, elevated blocking hemorrhage or hyperplastic pigment). Baseline was defined as the last non-missing measurement before the initiation of study treatment.

    Time frame: Baseline (Day 1) and Weeks 32 and 56

  10. Change From Baseline in Total Choroidal Neovascularization Area by Fluorescein Angiography up to Week 56

    The total CNV area included the measured area of classic and occult components. Baseline was defined as the last non-missing measurement before the initiation of study treatment.

    Time frame: Baseline (Day 1) and Weeks 32 and 56

  11. Systemic Exposure to EYP-1901 Measured Through Plasma Levels up to Week 56

    Blood samples were collected at the study visits to determine the EYP-1901 and its main metabolite concentrations.

    Time frame: Up to Week 56

  12. Ocular Exposure to EYP-1901 Measured Through Aqueous Humor (AH) Levels up to Week 32

    The AH samples were collected at the study visits to determine the EYP-1901 and its main metabolite concentrations.

    Time frame: Up to Week 32

  13. Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events up to Week 56

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational or marketed (medicinal) product and that does not necessarily have a causal relationship with the product. An serious AE is any AE that results in one of the following outcomes: death; life-threatening; requires in-patient hospitalization; results in a persistent or significant disability/incapacity; congenital anomaly/birth defect; other important medical event. The TEAEs are AEs that occur after the first dose of study treatment. administration.

    Time frame: From the study drug administration (Day 1) up to end of the study, approximately 56 weeks.

07

Results

Posted Oct 2, 2025
Limitations and caveats
For the events of endophthalmitis in the Serious Adverse Events (SAE) table, none were considered related to EYP-1901. In the aflibercept treatment group, these events were considered related to the injection procedure or were not treatment-related. In the EYP-1901 treatment group, these events were considered related to the supplemental injection procedure (with aflibercept), the paracentesis for aqueous humor collection, or were not treatment-related.

Participant flow

This Phase 2 prospective, randomized, double-masked study was conducted in previously treated subjects with wet age-related macular degeneration (wAMD) at 39 sites in the United States between 30 June 2022 and 24 April 2024.

Participant flow — Overall Study
MilestoneAflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcg
Started545354
Completed524752
Not completed262
Withdrew: Adverse event: ocular - study eye010
Withdrew: Adverse event: non-ocular010
Withdrew: Lost to follow-up100
Withdrew: Protocol deviation020
Withdrew: Withdrawal by subject101
Withdrew: Death020
Withdrew: Discontinued study without receiving study drug001

Outcome measures

PrimaryAverage Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 32

The BCVA was measured according to the standard procedure originally developed for Early Treatment Diabetic Retinopathy Study (ETDRS). The ETDRS letter score calculated when 20 or more letters were read correctly at 4.0 meters; the visual acuity letter score was equal to the total number of letters read correctly at 4.0 meters plus 30. The score ranges from 0 (worse) to 100 (best). Higher scores indicate positive outcome measure. Baseline was defined as the last non-missing measurement before the initiation of study treatment.

Time frame:
Baseline (Day 1) and Weeks 28 and 32
Reported as:
Least squares mean · score on a scale
Average Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 32
score on a scaleAflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcg
Average Change in Best Corrected Visual Acuity (BCVA) From Baseline Averaged Over Weeks 28 and 321.17 ± 0.8301.05 ± 0.8660.87 ± 0.841
Statistical analysis
  • Aflibercept 2 mg vs EYP-1901 2060 mcg · Mixed Model for Repeated Measures (MMRM) · p = 0.919 · Least square (ls) mean: -0.12 · 95% CI -2.48 to 2.24
  • Aflibercept 2 mg vs EYP-1901 3090 mcg · MMRM · p = 0.795 · Ls mean: -0.31 · 95% CI -2.63 to 2.02
SecondaryChange From Baseline in Best Corrected Visual Acuity up to Week 56

The BCVA was measured according to the standard procedure originally developed for ETDRS. The ETDRS letter score calculated when 20 or more letters were read correctly at 4.0 meters; the visual acuity letter score was equal to the total number of letters read correctly at 4.0 meters plus 30. The score ranges from 0 (worse) to 100 (best). Higher scores indicate positive outcome measure. Baseline was defined as the last non-missing measurement before the initiation of study treatment.

Time frame:
Baseline (Day 1) and Weeks 32 and 56
Reported as:
Mean · score on a scale
Change From Baseline in Best Corrected Visual Acuity up to Week 56
score on a scaleAflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcg
Baseline (Day 1)73.4 ± 9.4873.9 ± 7.9074.9 ± 7.68
Week 321.6 ± 6.811.0 ± 6.450.8 ± 5.22
Week 561.1 ± 8.550.3 ± 8.10-1.9 ± 7.83
SecondaryPercentage of Subjects With >=5, >=10, and >=15 BCVA Letter Change From Baseline up to Week 56

The BCVA was measured according to the standard procedure originally developed for ETDRS. The ETDRS letter score calculated when 20 or more letters were read correctly at 4.0 meters; the visual acuity letter score was equal to the total number of letters read correctly at 4.0 meters plus 30. The score ranges from 0 (worse) to 100 (best). Higher scores indicate positive outcome measure. Baseline was defined as the last non-missing measurement before the initiation of study treatment.

Time frame:
Baseline (Day 1) and Weeks 32 and 56
Reported as:
Number · percentage of subjects
Percentage of Subjects With >=5, >=10, and >=15 BCVA Letter Change From Baseline up to Week 56
percentage of subjectsAflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcg
Week 32: >=5 BCVA Letter Gain34.025.021.2
Week 32: >=5 BCVA Letter Loss13.220.811.5
Week 32: >=10 BCVA Letter Gain5.710.45.8
Week 32: >=10 BCVA Letter Loss5.76.33.8
Week 32: >=15 BCVA Letter Gain1.92.10
Week 32: >=15 BCVA Letter Loss1.901.9
Week 56: >=5 BCVA Letter Gain32.723.415.4
Week 56: >=5 BCVA Letter Loss23.123.432.7
Week 56: >=10 BCVA Letter Gain17.312.83.8
Week 56: >=10 BCVA Letter Loss11.510.613.5
Week 56: >=15 BCVA Letter Gain1.94.30
Week 56: >=15 BCVA Letter Loss7.74.33.8
SecondaryPercentage of Subjects Not Receiving Supplemental Injection of Aflibercept up to Week 56

Supplemental therapy was any unscheduled injection of aflibercept, whether or not a subject had met rescue criteria. For the aflibercept arm, any aflibercept injection following Week 8 which did not occur at Weeks 16, 24, 32, 40, 48, or 56, was supplemental therapy. For either of the EYP-1901 arms, any aflibercept injection following the Week 8 visit was supplemental therapy.

Time frame:
Weeks 32 and 56
Reported as:
Number · percentage of subjects
Percentage of Subjects Not Receiving Supplemental Injection of Aflibercept up to Week 56
percentage of subjectsAflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcg
Week 3294.362.563.5
Week 5682.742.646.2
SecondaryMedian Time to First Supplemental Aflibercept Injection in the Study Eye Following the EYP-1901 Dose at Week 8

Time to first supplemental aflibercept injection following Week 8 study treatment was defined as the date of the first supplemental aflibercept injection minus the date of the Week 8 study treatment administration, divided by 7 days per week. Subjects who did not receive any supplemental aflibercept injection following study treatment administration at Week 8 were censored at their date of last visit (those who completed) or date of last contact (those who discontinued the study early).

Time frame:
From Week 8 to Week 56
Reported as:
Median · week
Median Time to First Supplemental Aflibercept Injection in the Study Eye Following the EYP-1901 Dose at Week 8
weekEYP-1901 2060 mcgEYP-1901 3090 mcg
Median Time to First Supplemental Aflibercept Injection in the Study Eye Following the EYP-1901 Dose at Week 837.00 (20.14 to NA)40.79 (20.00 to NA)
SecondaryNumber of Aflibercept Intravitreal Injections up to Week 56 (Including Loading Dose)

Normalized number of aflibercept injections including loading dose was calculated as (number of aflibercept injections received plus all loading doses received) / (time within study period in months), multiplied by 6 months (Week 32) or 12 months (Week 56).

Time frame:
Weeks 32 and 56
Reported as:
Mean · normalized no. of aflibercept injections
Number of Aflibercept Intravitreal Injections up to Week 56 (Including Loading Dose)
normalized no. of aflibercept injectionsAflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcg
Week 323.23 ± 0.3572.06 ± 0.5832.13 ± 0.747
Week 566.33 ± 0.7543.45 ± 1.7383.36 ± 1.854
SecondaryMean Change From Baseline in Central Subfield Thickness (CST) by Spectral-Domain - Optical Coherence Tomography (SD-OCT) up to Week 56

The SD-OCT assessments in study eye was taken by a study-certified OCT technician according to the standardized procedures described in the Study Manual. Baseline was defined as the last non-missing measurement before the initiation of study treatment.

Time frame:
Baseline (Day 1) and Weeks 32 and 56
Reported as:
Mean · micron
Mean Change From Baseline in Central Subfield Thickness (CST) by Spectral-Domain - Optical Coherence Tomography (SD-OCT) up to Week 56
micronAflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcg
Baseline (Day 1)265.7 ± 39.86264.5 ± 40.26262.9 ± 34.46
Week 325.4 ± 44.5217.8 ± 42.2710.6 ± 38.45
Week 568.1 ± 58.3312.2 ± 49.8316.7 ± 51.98
SecondaryChange From Baseline in Height of Subretinal Fluid by Spectral-Domain - Optical Coherence Tomography up to Week 56

The SD-OCT assessments in study eye was taken by a study-certified OCT technician according to the standardized procedures described in the Study Manual. Baseline was defined as the last non-missing measurement before the initiation of study treatment.

Time frame:
Baseline (Day 1) and Weeks 32 and 56
Reported as:
Mean · micron
Change From Baseline in Height of Subretinal Fluid by Spectral-Domain - Optical Coherence Tomography up to Week 56
micronAflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcg
Baseline (Day 1)46.87 ± 27.75349.84 ± 32.78650.71 ± 28.507
Week 3233.05 ± 62.35818.75 ± 48.19710.68 ± 37.686
Week 5622.87 ± 69.50939.50 ± 62.1835.95 ± 38.866
SecondaryPercentage of Subjects With No Detectable Intraretinal Fluid/Cysts in the Central Subfield up to Week 56

The percentage of subjects with no detectable intraretinal fluid/cysts in the central subfield were summarized by scheduled visit and for any time post-baseline visits. Intraretinal fluid was assessed for the categories 'Absent', 'Present, not clinically significant', 'Present, clinically significant' and 'Not Done'. If intraretinal fluid assessment at any scheduled visit fell under the category 'Absent or Present, not clinically significant', then it was considered as no detectable intraretinal fluid in that scheduled visit.

Time frame:
Weeks 32 and 56
Reported as:
Number · percentage of subjects
Percentage of Subjects With No Detectable Intraretinal Fluid/Cysts in the Central Subfield up to Week 56
percentage of subjectsAflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcg
Week 3262.352.151.9
Week 5659.659.651.9
SecondaryChange From Baseline in Total Lesion Area by Fluorescein Angiography (FA) up to Week 56

The total lesion area was defined as the active vascular component \[classic and occult choroidal neovascularization (CNV)\] and the non-vascular/fibrotic component (fibrosis, serous pigment epithelial detachment, elevated blocking hemorrhage or hyperplastic pigment). Baseline was defined as the last non-missing measurement before the initiation of study treatment.

Time frame:
Baseline (Day 1) and Weeks 32 and 56
Reported as:
Mean · millimeter square (mm^2)
Change From Baseline in Total Lesion Area by Fluorescein Angiography (FA) up to Week 56
millimeter square (mm^2)Aflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcg
Baseline (Day 1)5.06884 ± 4.5475715.48285 ± 5.4886824.82169 ± 4.325932
Week 321.24141 ± 2.8622561.07111 ± 2.6263691.13971 ± 2.024426
Week 561.56516 ± 3.2264031.84557 ± 4.1740532.22914 ± 3.696873
SecondaryChange From Baseline in Total Choroidal Neovascularization Area by Fluorescein Angiography up to Week 56

The total CNV area included the measured area of classic and occult components. Baseline was defined as the last non-missing measurement before the initiation of study treatment.

Time frame:
Baseline (Day 1) and Weeks 32 and 56
Reported as:
Mean · mm^2
Change From Baseline in Total Choroidal Neovascularization Area by Fluorescein Angiography up to Week 56
mm^2Aflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcg
Baseline (Day 1)5.06 ± 4.5515.44 ± 5.5314.77 ± 4.322
Week 321.15 ± 2.9681.10 ± 2.6741.19 ± 2.033
Week 561.46 ± 3.3541.14 ± 5.3452.31 ± 3.656
SecondarySystemic Exposure to EYP-1901 Measured Through Plasma Levels up to Week 56

Blood samples were collected at the study visits to determine the EYP-1901 and its main metabolite concentrations.

Time frame:
Up to Week 56
Reported as:
Mean · picogram per milliliter
Systemic Exposure to EYP-1901 Measured Through Plasma Levels up to Week 56
picogram per milliliterAflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcg
Week 8 - EYP-1901 concentration—0.000 ± 0.00000.000 ± 0.0000
Week 8 - metabolite concentration—0.00 ± 0.000.00 ± 0.00
Week 20 - EYP-1901 concentration—23.206 ± 8.887127.121 ± 10.0821
Week 20 - metabolite concentration—1.01 ± 2.272.46 ± 3.86
Week 32 - EYP-1901 concentration—14.333 ± 6.109819.335 ± 7.3783
Week 32 - metabolite concentration—0.00 ± 0.000.598 ± 2.21
Week 44 - EYP-1901 concentration—10.292 ± 5.208614.180 ± 4.9819
Week 44 - metabolite concentration—0.00 ± 0.000.485 ± 1.69
Week 56 - EYP-1901 concentration—7.733 ± 4.968410.392 ± 5.2315
Week 56 - metabolite concentration—0.00 ± 0.000.121 ± 0.867
SecondaryOcular Exposure to EYP-1901 Measured Through Aqueous Humor (AH) Levels up to Week 32

The AH samples were collected at the study visits to determine the EYP-1901 and its main metabolite concentrations.

Time frame:
Up to Week 32
Reported as:
Mean · nanogram per milliliter
Ocular Exposure to EYP-1901 Measured Through Aqueous Humor (AH) Levels up to Week 32
nanogram per milliliterAflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcg
Week 8 - EYP-1901 concentration—0.000 ± 0.00000.000 ± 0.0000
Week 8 - metabolite concentration—0.00 ± 0.000.00 ± 0.00
Week 20 - EYP-1901 concentration—17.426 ± 13.714325.066 ± 18.8594
Week 20 - metabolite concentration—0.00 ± 0.000.00 ± 0.00
Week 32 - EYP-1901 concentration—11.890 ± 10.843619.813 ± 15.0833
Week 32 - metabolite concentration—0.00 ± 0.000.00 ± 0.00
SecondaryNumber of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events up to Week 56

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a patient or clinical investigation subject administered an investigational or marketed (medicinal) product and that does not necessarily have a causal relationship with the product. An serious AE is any AE that results in one of the following outcomes: death; life-threatening; requires in-patient hospitalization; results in a persistent or significant disability/incapacity; congenital anomaly/birth defect; other important medical event. The TEAEs are AEs that occur after the first dose of study treatment. administration.

Time frame:
From the study drug administration (Day 1) up to end of the study, approximately 56 weeks.
Reported as:
Count of participants · Participants
Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious Treatment-Emergent Adverse Events up to Week 56
ParticipantsAflibercept 2 mg - Study EyeAflibercept 2 mg - Fellow EyeAflibercept 2 mg - SystemicEYP-1901 2060 mcg - Study EyeEYP-1901 2060 mcg - Fellow EyeEYP-1901 2060 mcg - SystemicEYP-1901 3090 mcg - Study EyeEYP-1901 3090 mcg - Fellow EyeEYP-1901 3090 mcg - Systemic
any TEAEs302140301128302039
any Serious TEAEs216006409

Adverse events

Collected over TEAEs were collected from the study drug administration (Day 1) up to end of the study, approximately 56 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept 2 mg - Study Eye0/54 (0%)2/54 (3.7%)30/54 (55.6%)
Aflibercept 2 mg - Fellow Eye0/54 (0%)1/54 (1.9%)17/54 (31.5%)
Aflibercept 2 mg - Systemic0/54 (0%)6/54 (11.1%)33/54 (61.1%)
EYP-1901 2060 mcg - Study Eye0/50 (0%)0/50 (0%)30/50 (60%)
EYP-1901 2060 mcg - Fellow Eye0/50 (0%)0/50 (0%)11/50 (22%)
EYP-1901 2060 mcg - Systemic2/50 (4%)6/50 (12%)28/50 (56%)
EYP-1901 3090 mcg - Study Eye0/52 (0%)4/52 (7.7%)30/52 (57.7%)
EYP-1901 3090 mcg - Fellow Eye0/52 (0%)0/52 (0%)20/52 (38.5%)
EYP-1901 3090 mcg - Systemic0/52 (0%)9/52 (17.3%)39/52 (75%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventAflibercept 2 mg - Study EyeAflibercept 2 mg - Fellow EyeAflibercept 2 mg - SystemicEYP-1901 2060 mcg - Study EyeEYP-1901 2060 mcg - Fellow EyeEYP-1901 2060 mcg - SystemicEYP-1901 3090 mcg - Study EyeEYP-1901 3090 mcg - Fellow EyeEYP-1901 3090 mcg - Systemic
EndophthalmitisInfections and infestations2/540/540/540/500/500/503/520/520/52
Angina pectorisCardiac disorders0/540/540/540/500/501/500/520/520/52
Cardiac arrestCardiac disorders0/540/540/540/500/501/500/520/520/52
Cardiac failureCardiac disorders0/540/540/540/500/501/500/520/520/52
Cardiac failure congestiveCardiac disorders0/540/540/540/500/501/500/520/520/52
Gastric infectionInfections and infestations0/540/540/540/500/501/500/520/520/52
Septic shockInfections and infestations0/540/540/540/500/501/500/520/520/52
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/540/540/540/500/501/500/520/521/52
Supraventricular tachycardiaCardiac disorders0/540/540/540/500/500/500/520/521/52
Non-infectious endophthalmitisEye disorders0/540/540/540/500/500/501/520/520/52
Most frequent other events
Showing 10 of 29
Most frequent other events
EventAflibercept 2 mg - Study EyeAflibercept 2 mg - Fellow EyeAflibercept 2 mg - SystemicEYP-1901 2060 mcg - Study EyeEYP-1901 2060 mcg - Fellow EyeEYP-1901 2060 mcg - SystemicEYP-1901 3090 mcg - Study EyeEYP-1901 3090 mcg - Fellow EyeEYP-1901 3090 mcg - Systemic
Visual acuity reducedEye disorders3/542/540/541/502/500/508/522/520/52
Urinary tract infectionInfections and infestations0/540/543/540/500/505/500/520/528/52
HypertensionVascular disorders0/540/544/540/500/502/500/520/527/52
COVID-19Infections and infestations0/540/547/540/500/505/500/520/525/52
Conjunctival haemorrhageEye disorders4/541/540/546/501/500/503/520/520/52
Subretinal fluidEye disorders4/540/540/546/500/500/503/520/520/52
Retinal haemorrhageEye disorders1/543/540/542/500/500/506/521/520/52
Vitreous floatersEye disorders1/540/540/542/502/500/506/521/520/52
CataractEye disorders5/542/540/544/502/500/505/525/520/52
Posterior capsule opacificationEye disorders0/541/540/544/502/500/501/522/520/52

Baseline characteristics

Full Analysis Set (FAS) included all randomized subjects who received at least 1 dose of study treatment.

Age, Continuous
Age, Continuous(years)Aflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcgTotal
Mean75.9 ± 7.5976.4 ± 6.6675.4 ± 7.1975.9 ± 7.14
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcgTotal
Female29323596
Male25181760
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcgTotal
Hispanic or Latino0134
Not Hispanic or Latino534849150
Unknown or Not Reported1102
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Aflibercept 2 mgEYP-1901 2060 mcgEYP-1901 3090 mcgTotal
Asian1001
Black0000
White535051154
Not Reported0011
08

Study locations

67 sites
  • EyePoint Investigative Site
    Phoenix, Arizona 85053, United States
  • EyePoint Investigative Site
    Springdale, Arkansas 72762, United States
  • EyePoint Investigative Site
    Beverly Hills, California 90211, United States
  • EyePoint Investigative Site
    Campbell, California 95008, United States
  • EyePoint Investigative Site
    Encino, California 91436, United States
  • EyePoint Investigative Site
    Fullerton, California 92835, United States
  • EyePoint Investigative Site
    Glendale, California 91203, United States
  • EyePoint Investigative Site
    Huntington Beach, California 92647, United States
  • EyePoint Investigative Site
    Irvine, California 92697, United States
  • EyePoint Investigative Site
    Pasadena, California 91107, United States
  • EyePoint Investigative Site
    Poway, California 92064, United States
  • EyePoint Investigative Site
    Redlands, California 92373, United States
  • EyePoint Investigative Site
    Sacramento, California 95825, United States
  • EyePoint Investigative Site
    Walnut Creek, California 94598, United States
  • EyePoint Investigative Site
    Lakewood, Colorado 80228, United States
  • EyePoint Investigative Site
    Clearwater, Florida 33761, United States
  • EyePoint Investigative Site
    Coral Springs, Florida 33067, United States
  • EyePoint Investigative Site
    Lakeland, Florida 33805, United States
  • EyePoint Investigative Site
    Melbourne, Florida 32901, United States
  • EyePoint Investigative Site
    Miami, Florida 33143, United States
  • EyePoint Investigative Site
    Pensacola, Florida 32503, United States
  • EyePoint Investigative Site
    Sarasota, Florida 34239, United States
  • EyePoint Investigative Site
    St. Petersburg, Florida 33711, United States
  • EyePoint Investigative Site
    Tampa, Florida 33609, United States
  • EyePoint Investigative Site
    Winter Haven, Florida 33880, United States
  • EyePoint Investigative Site
    Marietta, Georgia 30060, United States
  • EyePoint Investigative Site
    ‘Aiea, Hawaii 96701, United States
  • EyePoint Investigative Site
    Chicago, Illinois 60616, United States
  • EyePoint Investigative Site
    Lemont, Illinois 60439, United States
  • EyePoint Investigative Site
    Carmel, Indiana 46290, United States
  • EyePoint Investigative Site
    West Des Moines, Iowa 50266, United States
  • EyePoint Investigative Site
    Baltimore, Maryland 21209, United States
  • EyePoint Investigative Site
    Hagerstown, Maryland 21740, United States
  • EyePoint Investigative Site
    Owings Mills, Maryland 21117, United States
  • EyePoint Investigative Site
    Boston, Massachusetts 02114, United States
  • EyePoint Investigative Site
    Springfield, Massachusetts 01107, United States
  • EyePoint Investigative Site
    Grand Rapids, Michigan 49446, United States
  • EyePoint Investigative Site
    Saint Louis, Michigan 55416, United States
  • EyePoint Investigative Site
    St Louis, Missouri 63128, United States
  • EyePoint Investigative Site
    Reno, Nevada 89502, United States
  • EyePoint Investigative Site
    Teaneck, New Jersey 07666, United States
  • EyePoint Investigative Site
    Great Neck, New York 11021, United States
  • EyePoint Investigative Site
    Hauppauge, New York 11788, United States
  • EyePoint Investigative Site
    Liverpool, New York 13088, United States
  • EyePoint Investigative Site
    Shirley, New York 11967, United States
  • EyePoint Investigative Site
    Asheville, North Carolina 28803, United States
  • EyePoint Investigative Site
    Wake Forest, North Carolina 27587, United States
  • EyePoint Investigative Site
    Eugene, Oregon 97401, United States
  • EyePoint Investigative Site
    Portland, Oregon 97239, United States
  • EyePoint Investigative Site
    Springfield, Oregon 97488, United States
  • EyePoint Investigative Site
    Charleston, South Carolina 29414, United States
  • EyePoint Investigative Site
    West Columbia, South Carolina 29169, United States
  • EyePoint Investigative Site
    Germantown, Tennessee 38138, United States
  • EyePoint Investigative Site
    Nashville, Tennessee 37203, United States
  • EyePoint Investigative Site
    Abilene, Texas 79606, United States
  • EyePoint Investigative Sites
    Austin, Texas 78750, United States
  • EyePoint Investigative Site
    Dallas, Texas 75231, United States
  • EyePoint Investigative Sites
    Houston, Texas 77025, United States
  • EyePoint Investigative Site
    McAllen, Texas 78503, United States
  • EyePoint Investigative Site
    Plano, Texas 75075, United States
  • EyePoint Investigative Site
    San Antonio, Texas 78240, United States
  • EyePoint Investigative Site
    The Woodlands, Texas 77384, United States
  • EyePoint Investigative Site
    Salt Lake City, Utah 84107, United States
  • EyePoint Investigative Site
    Fairfax, Virginia 22031, United States
  • EyePoint Investigative Site
    Lynchburg, Virginia 24502, United States
  • EyePoint Investigative Site
    Warrenton, Virginia 20186, United States
  • EyePoint Investigative Site
    Silverdale, Washington 98383, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Nov 2023, 16 months.

Results were first posted in Oct 2025, 1 year 10 months after primary completion.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 16 months is below that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2022
First posted
May 19, 2022
StartActual
Jun 30, 2022
Primary completionActual
Nov 29, 2023
CompletionActual
Apr 24, 2024
Results first posted
Oct 2, 2025
Last update
Oct 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05381948
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
May 19, 2022
Start date
Jun 30, 2022
Primary completion
Nov 29, 2023
Completion
Apr 24, 2024
Results posted
Oct 2, 2025
Last update
Oct 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vorolanib

Start the discussion